<unk>  (LY3009806, IMC-1121B, trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.
Ramucirumab
Ustekinumab
Emapalumab
Olaratumab
Evolocumab
Avelumab
Anifrolumab
Burosumab